Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accounts Payables (2022 - 2025)

Zentalis Pharmaceuticals has reported Accounts Payables over the past 4 years, most recently at $7.2 million for Q4 2025.

  • Quarterly results put Accounts Payables at $7.2 million for Q4 2025, down 3.09% from a year ago — trailing twelve months through Dec 2025 was $7.2 million (down 3.09% YoY), and the annual figure for FY2025 was $7.2 million, down 3.09%.
  • Accounts Payables for Q4 2025 was $7.2 million at Zentalis Pharmaceuticals, up from $7.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for ZNTL hit a ceiling of $20.4 million in Q2 2024 and a floor of $3.7 million in Q2 2025.
  • Median Accounts Payables over the past 4 years was $10.9 million (2022), compared with a mean of $10.8 million.
  • Biggest five-year swings in Accounts Payables: soared 66.11% in 2024 and later tumbled 81.81% in 2025.
  • Zentalis Pharmaceuticals' Accounts Payables stood at $11.2 million in 2022, then soared by 32.71% to $14.9 million in 2023, then tumbled by 50.17% to $7.4 million in 2024, then dropped by 3.09% to $7.2 million in 2025.
  • The last three reported values for Accounts Payables were $7.2 million (Q4 2025), $7.0 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.